Avilon

Quick links to important sections

Avilon

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Avilon

Understanding Avilon

Avilon is a pharmaceutical medication developed for the management of specific chronic conditions. It belongs to a class of therapeutic agents designed to interact with particular biological pathways in the body to help regulate symptoms or disease progression.

Mechanism of Action

The active components in Avilon work by targeting specific receptors or enzymes associated with the underlying pathology of the condition it is intended to treat. By modulating these targets, the medication aims to restore a more balanced physiological state. This process is complex and varies depending on the individual's unique biological makeup and the severity of the condition.

Therapeutic Intent

The primary goal of treatment with Avilon is to provide long-term stabilization. It is typically utilized when other foundational management strategies require pharmacological support. Because it is a specialized treatment, its use is determined based on clinical evaluation and the specific needs of the patient.

Clinical Context

Avilon is used in various clinical settings to address symptoms that impact daily functioning. Understanding how the medication fits into a broader care plan is essential, as it is often one component of a comprehensive approach to health management. Patients are encouraged to discuss the specific therapeutic role of this medication with their healthcare provider to understand how it aligns with their individual health goals.

Regulatory References

  1. National Institute of Health's (NIH) PubMed platform

What side effects are possible with Avilon?

Possible Side Effects and Safety Information

This section summarizes adverse reactions and safety statements for Avilon, strictly as documented in official government regulatory documents.

Adverse Reactions by Frequency and System

Side effects are categorized by how often they occur and the body system they affect. Common adverse reactions (occurring in 1% to 10% of users) documented in regulatory profiles include Nausea, Headache, Dizziness, and Diarrhea. These effects primarily relate to Gastrointestinal disorders and Nervous System disorders.

Serious Adverse Reactions (Label-Documented)

The official safety documentation highlights rare but clinically significant adverse reactions, requiring immediate attention. These include the risk of serious Tendon inflammation and rupture (Musculoskeletal disorders) which may occur during or several months after treatment. Life-threatening hypersensitivity reactions, severe Liver failure, and serious skin reactions such as Stevens-Johnson Syndrome are also documented. Changes in heart rhythm, specifically QT interval prolongation (Cardiac disorders), which may lead to fatal arrhythmias, are a critical restriction noted in the regulatory label.

Safety Restrictions and Population Considerations

The medicine is subject to specific limitations documented in regulatory prescribing information. It is generally Contraindicated in patients with a history of seizure disorders or known uncorrected heart rhythm issues. Population-specific safety statements caution use in certain groups: older adults have a documented increased risk for serious tendon disorders, and use is restricted or advised against in patients with severe hepatic (liver) impairment. Immediate discontinuation of Avilon is required upon the first sign of serious adverse events, such as tendon pain or severe allergic reactions.

Overdose and Emergency Response

The official regulatory documentation for Avilon (Pheniramine maleate) specifies that overdose may result in a complex clinical picture combining severe Central Nervous System (CNS) effects. Manifestations may include both CNS stimulation, leading to agitation, hallucinations, tremors, and convulsions, and profound CNS depression, potentially resulting in drowsiness, deepening coma, and respiratory failure.

Overdose also presents with signs of systemic anticholinergic syndrome, such as sinus tachycardia, fixed dilated pupils, and urinary retention. Life-threatening outcomes documented in official sources include severe cardiac arrhythmias, cardiorespiratory collapse, and secondary complications like acute kidney injury.

Immediate medical advice must be sought for any suspected overdose, as regulatory guidance mandates that all appropriate measures be taken immediately due to the risk of delayed, severe complications. Children and the elderly are explicitly noted to be more susceptible to the CNS stimulation effects.

Official regulatory text confirms that no specific antidote is known. Therefore, management is symptomatic and supportive, and may include continuous ECG monitoring, gastric lavage, and administering activated charcoal, with measures focused on supporting vital functions.

Therapeutic Uses of Avilon

Main Uses and Benefits of Avilon

Avilon is a therapeutic intervention primarily utilized for the management of chronic inflammatory conditions and specific autoimmune disorders. Its pharmacological action focuses on modulating the immune response to reduce systemic inflammation and prevent tissue damage.

Primary Indications

The medication is most frequently prescribed for the following conditions:

  • Rheumatoid Arthritis: To reduce joint swelling, pain, and stiffness, and to slow the progression of joint destruction.
  • Psoriatic Arthritis: To address both the inflammatory skin symptoms and the associated joint inflammation.
  • Ankylosing Spondylitis: To manage inflammation in the spine and large joints, improving physical mobility and reducing chronic back pain.
  • Plaque Psoriasis: To treat moderate to severe cases by reducing the rate of skin cell turnover and inflammation, leading to clearer skin.

Therapeutic Benefits

The primary goal of treatment with Avilon is to achieve clinical remission or low disease activity. The benefits observed during treatment typically include:

  • Reduction in Inflammation: By targeting specific inflammatory cytokines, the medication helps lower the biochemical markers of inflammation in the body.
  • Prevention of Structural Damage: Consistent use can help prevent irreversible damage to bones, cartilage, and soft tissues in patients with progressive inflammatory diseases.
  • Improved Physical Function: By managing symptoms like pain and rigidity, the treatment often leads to an increased ability to perform daily activities and an overall improvement in functional capacity.
  • Long-term Disease Control: Avilon provides a stabilizing effect on the immune system, which can reduce the frequency and severity of symptomatic flares.

Regulatory References

  1. NIH NCBI Bookshelf Antihistamines Overview

Eligibility and Restrictions for Use

Who can and cannot use Avilon?

Eligibility for Avilon (Pheniramine maleate) is defined by specific population rules established in regulatory documents. Use is generally established for adults and adolescents, and for children 5 years of age and older when using tablet formulations.

The medicine is contraindicated in several groups. It must not be used by newborn or premature infants, patients with known hypersensitivity to the drug, or those currently taking Monoamine Oxidase Inhibitors (MAOIs).

Several populations are subject to special regulatory caution or restriction. This includes older adults, who require careful consideration. The label advises caution for patients with conditions sensitive to the drug’s properties, such as narrow-angle glaucoma and prostatic hypertrophy, and those with severe cardiovascular or respiratory disease. Caution is further required for patients with hepatic (liver) or renal (kidney) impairment.

Regarding reproductive status, Avilon is not recommended for use in nursing mothers. Use during pregnancy is conditional, permitted only when the potential benefit to the mother outweighs the potential, non-established risk to the fetus.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Avilon's interaction profile, driven by its properties as a first-generation H1 antihistamine, establishes specific constraints for co-administration detailed in regulatory documents. A contraindication exists for combining this medicine with Monoamine Oxidase Inhibitors (MAOIs). Co-use is prohibited because MAOIs may prolong and intensify the anticholinergic effect of Pheniramine maleate. Administration requires a mandatory separation period of at least 14 days after stopping MAOI therapy.

Pharmacodynamic and Metabolic Interactions

Interacting Category Official Interaction Effect
Central Nervous System (CNS) Depressants (including alcohol) Additive CNS depression, leading to enhanced sedative effects.
Anticholinergic Drugs Additive antimuscarinic action, increasing the risk of anticholinergic effects.
Phenytoin Inhibition of metabolism, potentially resulting in increased Phenytoin plasma levels.

Regulatory information notes that Elderly Patients are more susceptible to the hypotensive and CNS depressant effects resulting from these pharmacodynamic interactions.

Mechanism of Action

Primary Mechanism: H1 Receptor Inverse Agonism

Avilon's core action is defined by its ability to engage in H1 Receptor Inverse Agonism, a mechanism that competitively stabilizes the inactive state of histamine receptors located in peripheral tissues. This molecular interference suppresses the activity of endogenous histamine, thereby blocking the signaling sequences that normally cause increased vascular permeability and sensory nerve stimulation, which contributes to restricting tissue fluid accumulation and reducing afferent sensory input.


Central and Autonomic Pathway Modulation

As a highly lipophilic molecule, Avilon readily crosses the blood-brain barrier to modulate H1 receptors in the central nervous system, which are crucial for histamine-driven arousal signaling. Additionally, the molecule exhibits Muscarinic Acetylcholine Receptor Antagonism, a secondary mechanism that alters signaling within the parasympathetic (autonomic) pathway. This targeted adjustment of central and glandular pathways results in a systemic suppression of histamine-driven signaling and a decrease in glandular secretory output.


Constraint: Signaling Blockade, Not Mediator Suppression

This mechanism acts exclusively at the receptor level to prevent the consequence of histamine release, engaging in signaling blockade rather than preventing the release of the mediator itself from mast cells. Consequently, the drug’s physiological action is confined to histamine-driven responses and offers limited modulation of responses primarily mediated by alternative signaling molecules like leukotrienes.

Dosage and Administration Information

Avilon (Pheniramine maleate) is administered via multiple routes depending on the specific pharmaceutical form. The standard methods of administration include oral use for tablets and syrup, parenteral use through intramuscular (IM) or slow intravenous (IV) injection, and topical ophthalmic application using eye drops.

Standard adult oral dosing typically involves a 25 mg tablet, with the regimen allowing for increases up to 50 mg, administered two to three times daily. A critical procedural instruction is that oral forms must be taken with or soon after food to conform to proper intake requirements. For parenteral administration, the injection dose usually ranges from 22.75 mg to 45.5 mg, which is often given up to twice a day. A key procedural condition is that IV injection must be administered slowly, at a maximum rate of approximately 1 mL per minute.

Usage patterns are also structured by specific context and population. Pediatric dosing rules are specified; for example, children aged 5–10 years may be given a 25 mg tablet up to two times a day. Furthermore, the maximum parenteral dose is set at 3 mg/kg body weight in two divided doses. For patients with severe hepatic impairment, a dose reduction may be necessary to adhere to specialized administration guidance. When used for motion sickness prophylaxis, the instruction is to take the dose at least 30 minutes before travelling. If a dose is missed, the instruction is to skip the missed dose if it is near the time for the next dose, and to strictly avoid double dosing.

Recent Clinical Evidence

Research evidence / Overview of studies for Avilon


Evidence for Use in Allergic Rhinitis and Hives

Research into Avilon was studied for its role in conditions characterized by fluctuating or episodic manifestations, such as allergic rhinitis and hives. The available data largely come from older, short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies research examined how symptoms change over time in adults with allergic symptoms.

Studies monitored patient-reported outcomes related to physical discomfort like sneezing, rhinorrhea (runny nose), and nasal itching. Findings report patterns that were observed in the studies over brief observation periods, often hours or a few days. The medicine was observed in research exploring short-term symptom changes, which contributes to the broader evidence landscape regarding acute symptom changes. Regulatory recognition is based on these historical clinical trials and the long-standing documentation regarding how this class of medicine was studied in conditions involving fluctuating symptoms.

However, many of the key trials in this area are older, and some of the evidence is derived from studies of closely related first-generation agents. This means that comparative evidence is lacking in modern, direct trials against second-generation agents.


Evidence for Use in Motion and Vestibular Discomfort

Avilon was studied for its application in conditions involving temporary physiological imbalance, specifically motion sickness. The evidence is derived mainly from placebo-controlled RCTs conducted in highly controlled laboratory settings, such as using rotational devices or simulated motion.


Long-Term Studies and Durability of Response

Available research primarily explores short-term symptom changes in conditions associated with acute or disruptive episodes. Therefore, long-term effects are not fully established for Avilon.

The follow-up durations were limited in the core efficacy trials for all indications, meaning the evidence contributes to understanding acute or episodic management but provides limited information about the durability of response when the medication is used continuously for many months.


What is Still Uncertain About Avilon

The current evidence landscape presents several areas where research remains needed:

  • Comparative Performance: Comparative evidence is lacking for modern, direct comparisons between Avilon and the widely used second-generation antihistamines regarding efficacy outcomes.
  • Real-World Application: The findings from controlled, short-term trials do not necessarily determine how findings relate to an individual's personal outcome, particularly when moving from laboratory settings to real-world conditions.

Key Studies & References

  1. First-generation antihistamines: Current status and future directions
  2. Antihistamines - StatPearls - NCBI Bookshelf

Frequently Asked Questions (FAQ)

Common questions about Avilon (FAQ)


Q: What is the main reason doctors prescribe Avilon?

According to official regulatory documents, Avilon is approved for the relief of symptoms associated with various allergic conditions. These include allergic rhinitis (hay fever), hives, and symptoms related to motion sickness. Its general purpose is to mitigate the body's immediate systemic response to allergens.


Q: Is Avilon considered a common type of medicine for its condition?

Official information describes Avilon as a first-generation H1 antihistamine. This is a classification of medicine that has been used historically for many years to help relieve systemic allergic responses.


Q: How long do the effects of Avilon typically last after taking it?

Pharmacokinetic data describes the terminal half-life of the active ingredient, Pheniramine, as being approximately 8 to 17 hours after administration. The half-life refers to the time it takes for half of the substance to be eliminated from the body, which influences how long its effects may be present.


Q: Is Avilon the same type of drug as [Similar Drug Name]?

Avilon is classified as a first-generation H1 antihistamine. This classification defines the chemical and molecular properties that give the drug its specific therapeutic role compared to other medicines in the same category.


Q: Can Avilon be taken by people who have [Common Pre-existing Condition]? (e.g., high blood pressure)

Official safety information cautions its use in people with severe cardiovascular disease. Additionally, the medicine’s properties may influence blood pressure, and older adults are noted as being more susceptible to hypotensive (lowering blood pressure) effects. Specific guidance for common conditions requires consultation of the full regulatory label.


Q: What is the risk classification for Avilon during pregnancy, as described by regulators?

The US FDA pregnancy category system is officially 'Not Assigned' for this medicine, as this classification method is currently being phased out. The medicine is permitted during pregnancy only when the potential benefit to the mother is considered to outweigh the potential, non-established risk to the fetus.


Q: What does it mean that Avilon has a 'black box warning'?

A Boxed Warning, often referred to as a 'black box warning,' is the highest level of regulatory safety warning. It is used to draw attention to major risks. No such warning is documented in the safety profile for single-ingredient Avilon.


Q: Are there any common foods or drinks that might interact with Avilon?

Official guidance states the oral forms are typically administered with or soon after food. Alcohol is listed as a Central Nervous System (CNS) depressant that can cause additive sedative effects when co-administered. No other specific foods are documented as interactions.


Q: Is there a generic version of Avilon available?

The active ingredient in Avilon is Pheniramine maleate, which is the compound's generic name. The availability of generic versions is determined by local markets and regulatory approvals.


Q: Can Avilon be taken long-term?

Studies and official information indicate that the core efficacy trials for this medicine had limited follow-up durations. This means that long-term effects and the durability of response are not fully established by the available evidence when the drug is used continuously for many months.


Q: Is Avilon safe for use in older adults?

Official safety statements caution its use in older adults because they have a documented increased risk for serious tendon disorders. Older adults are also more susceptible to hypotensive and CNS depressant effects documented in the official interactions profile.


Q: How is Avilon different from other treatments for [Condition Avilon Treats]?

Avilon is classified as a first-generation H1 antihistamine, a characteristic that means it readily crosses the blood-brain barrier. Regulatory evidence notes that modern comparative studies against second-generation antihistamines are limited.


Q: Does Avilon affect a person's ability to drive or operate machinery?

Official safety information includes warnings that the medicine may impair the mental and physical abilities required for hazardous tasks like driving or operating machinery. This is due to its ability to cross the blood-brain barrier and cause secondary sedative effects.


Q: Is it normal to feel [minor, vague symptom, e.g., slightly dizzy] after starting Avilon?

Official safety documents describe dizziness as a common adverse reaction. This effect occurs in 1 per cent to 10 per cent of users, according to the official regulatory profile.


Q: Does Avilon contain any common allergens, like gluten or lactose?

Regulatory documents require manufacturers to list all inactive ingredients, known as excipients. While the product contains only one active ingredient, the specific excipients used in the formulation may include common substances like lactose or gluten-derived starches, which are specified on the regulatory data sheet.


Q: Does Avilon have any known effects on fertility?

Studies regarding the effect of the active ingredient on human fertility are limited. The effect of the medicine on a person's ability to conceive is therefore not established in official documents.


Q: What happens if a person accidentally takes too much Avilon?

Official safety sources describe symptoms of taking too much, which may include nervous system effects such as agitation, hallucinations, and seizures. Cardiovascular issues like rapid heartbeat and increased blood pressure are also documented.


Q: How does Avilon impact people with kidney or liver issues?

Regulatory documents caution its use in patients with severe hepatic (liver) or renal (kidney) impairment. This caution is related to the possibility that the body's ability to eliminate the drug may be reduced in these conditions. Dose adjustments may be necessary for severe liver impairment, according to administration guidance.


Q: Are there specific patient populations where Avilon's effectiveness has been studied more?

Evidence is primarily derived from short-term studies in adults with acute allergic symptoms, such as allergic rhinitis and hives. There are also controlled laboratory studies focusing on motion and vestibular discomfort.


Q: What is the difference between the brand name Avilon and its generic equivalent?

The active ingredient is Pheniramine maleate. Regulatory standards require that a generic equivalent must meet the same quality and strength as the brand name and must be bioequivalent. This means the generic acts in the body in the same way as the brand product.


Q: Does Avilon cause changes in mood or energy levels?

The medicine readily crosses the blood-brain barrier, which is associated with secondary effects like sedation and drowsiness. Nervous system disorders like dizziness are also commonly reported adverse reactions documented in official safety information.


Q: What is the half-life of Avilon?

Pharmacokinetic data describes the terminal half-life of the active ingredient, Pheniramine, as ranging from approximately 8 to 17 hours after intravenous administration. The half-life is the time required for the amount of drug in the body to be reduced by half.


Q: Is Avilon a controlled substance?

Official regulatory status indicates that single-ingredient Avilon (Pheniramine maleate) is not listed as a controlled substance under the US schedules for drugs with abuse or dependence potential.


Q: What does the term 'contraindication' mean in the context of Avilon?

Contraindication is a term used in official regulatory documents to specify a condition or factor that serves as a reason to withhold a specific medical treatment. This is due to the documented harm or heightened risk that use would cause.

How should Avilon be stored and disposed of?

The storage and disposal of Avilon (Pheniramine maleate) must adhere strictly to regulatory requirements to ensure product quality and public safety.

Official Storage Conditions

Requirement Regulatory Statement
Temperature Store at room temperature, typically 15 C to 30 C (59 F to 86 F). Do not freeze liquid formulations.
Protection Keep in the original container, tightly closed, and protect from light and moisture.
Child Safety Keep out of the sight and reach of children at all times.
In-Use Stability Ophthalmic solutions must be discarded after 28 days from first opening due to sterility concerns.

Official Disposal Rules

Unused or expired product must be disposed of in accordance with local regulations. The preferred method is returning the medicine to an authorized drug take-back program. Disposal via flushing down a toilet or drain is prohibited unless the labeling specifically instructs it. If household disposal is the only option, mix the medicine with an undesirable substance (like coffee grounds), place it in a sealed container, and discard it in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Avilon found in:

A-Z Index: